XACT Robotics
8 Hatochen Street, 3rd Floor Industry Park North, Caesarea, 3079861, Israel
Overview
XACT Robotics is developing a robotic technology platform for needle steering in minimally invasive interventional procedures, such as biopsies and ablations. The technology is based on a novel approach to needle steering using a five-degrees-of-freedom robot, ongoing needle path calculation, and real-time closed-loop control. XACT Robotics’ technology actively compensates for breathing and patient movement during the procedure, enabling fast, accurate, and safe needle insertion to the desired target. Real-time closed-loop control coupled with complex angulation 3D trajectories allow small deviations from the originally planned pathway to be immediately detected and corrected without the need for needle reinsertion or patient repositioning. XACT Robotics’ technology can apply to a wide range of applications, procedures and target organs using different imaging systems within the image-guided and robot-assisted surgery market. Addressing the growing need for a novel technology to assist in CT-guided procedures, XACT Robotics is initially developing a system composed of a patient-mounted robot, a control unit connected to the CT and to the robot, and a workstation for procedure planning and observation.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Information Technology
- Medical Device
- Product Design
- Robotics
Investment portfolio
- CAPS Medical
Participated · Series A · Jul 2020
Caps Medical develops a highly selective, minimally invasive non-thermal plasma device to treat solid tumors. The platform attacks cancer cells without damaging surrounding healthy tissue and aims to trigger an immune response to target additional tumor-specific cells. The technology was developed in The Technion’s Plasma Lab in collaboration with Rambam Health Care Campus and was translated into a product by a team led by Ilan Uchitel at MEDX Xelerator. Founded in 2018 by MEDX Xelerator and based in Netanya, Israel, the company has been supported by MEDX Xelerator, with Boston Scientific and MEDX Ventures Group as major shareholders in the incubator. The $3.5M Series A will enable Caps Medical to perform its first clinical trial and further develop its solid tumor treatment portfolio. The company expects that study results will contribute toward achieving regulatory clearance in the U.S.; Harel Gadot will serve as Executive Chairman of Caps Medical’s board.